Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Leukemia, Myeloid, Acute 8Myelodysplastic Syndromes 4Leukemia, Myelomonocytic, Chronic 3Hematologic Neoplasms 2Solid Tumors 1Sarcoma 1Neoplasm Metastasis 1Leukemia, Myeloid 1Leukemia 1Glioblastoma 1

Interventions

Temozolomide 203Radiotherapy 118Bevacizumab 93Radiation 40Magnetic Resonance Spectroscopy 28Irinotecan 27Carmustine 25Surgical Procedures, Operative 24Lomustine 21Erlotinib Hydrochloride 19Chemotherapy, Adjuvant 18Carboplatin 17temsirolimus 13Drug Therapy 13O(6)-benzylguanine 12Nivolumab 12sargramostim 11Sirolimus 11Radiotherapy, Intensity-Modulated 11Radiotherapy, Conformal 11Sorafenib 10Radiosurgery 10Imatinib Mesylate 10Everolimus 10pembrolizumab 9motexafin gadolinium 9Vorinostat 9Thalidomide 8IL13-PE38 8Gefitinib 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Glioblastoma × glasdegib × Clear all
NCT03466450 2024-03-28

GEINOGLAS

Grupo Español de Investigación en Neurooncología

Phase 1/2 Completed
75 enrolled
CNS

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡